Welcome to our dedicated page for COHBAR news (Ticker: CWBR), a resource for investors and traders seeking the latest updates and insights on COHBAR stock.
CohBar Inc. (NASDAQ: CWBR) is a pioneering biotechnology company dedicated to transforming the way we approach chronic and age-related diseases. By harnessing the power of mitochondria through its innovative Mitochondria-Based Therapeutics (MBTs), the company is opening new frontiers in treating conditions that currently have limited or no treatment options.
CohBar's core business revolves around the discovery and development of therapeutic peptides encoded within the mitochondrial genome. These peptides, discovered by the company's founding scientists who are leaders in the fields of aging, metabolism, and mitochondrial genomics, have shown promise in addressing a wide array of diseases including type 2 diabetes, cancer, atherosclerosis, and neurodegenerative disorders.
Currently, CohBar is in the clinical-stage of development with several exciting projects in its pipeline. The company's most recent achievements include successful advancements in clinical trials and ongoing research into new peptide candidates. Financially, CohBar remains committed to maintaining a robust cash position to support its research and development activities.
Partnerships play a crucial role in CohBar's strategy. The company collaborates with leading academic institutions and other biotech firms to enhance its research capabilities and expedite the development of its therapeutic candidates.
Recent news highlights include the summary and financial results for the second quarter of 2023, showcasing CohBar's continuous progress and commitment to its mission. The company has also announced a proposed merger with Morphogenesis, which is expected to create significant synergies and enhance the combined entity's market presence.
For more detailed information about CohBar, its projects, and recent updates, visit their official website or follow them on LinkedIn. Investors are encouraged to contact the company directly at investors@cohbar.com for further inquiries.
CohBar, Inc. (NASDAQ: CWBR) has announced the completion of the final visit in the Phase 1b clinical study of CB4211 for nonalcoholic steatohepatitis (NASH) and obesity. Topline data is expected to be released in early July 2021. The study evaluates CB4211's safety and tolerability in obese subjects with nonalcoholic fatty liver disease (NAFLD). CB4211 is the first mitochondria-based therapeutic to undergo clinical testing, showing promising results in preclinical models. NASH affects around 30 million adults in the U.S., with no approved treatments available.
CohBar, Inc. (NASDAQ: CWBR) announced its CEO Steven Engle will present at the virtual Mitochondria-Targeted Drug Development Summit from April 27-29, 2021. Engle will participate in two panels discussing challenges and opportunities in mitochondrial therapies, specifically addressing age-related and mitochondrial diseases. Additionally, he will deliver a company overview on April 29, highlighting CohBar's innovative mitochondrial science and ongoing clinical programs, including its lead compound CB4211 in a Phase 1b trial for NASH and obesity.
CohBar (NASDAQ: CWBR) reported its fourth quarter 2020 financial results, highlighting significant advancements in its clinical studies. The company completed enrollment in the Phase 1b clinical study of CB4211 targeting NASH and obesity, with topline data expected by Q2 2021. Additionally, they nominated CB5138-3 for IPF treatment and initiated collaboration with NIAID for COVID-19 therapies. Cash reserves increased to $21 million, while the net loss was $4.7 million. CohBar plans to discuss these developments in a conference call on March 30, 2021.
CohBar, Inc. (NASDAQ: CWBR) announces completion of enrollment in the Phase 1b clinical study of CB4211 for treating nonalcoholic steatohepatitis (NASH) and obesity. Topline data is expected by the end of Q2 2021, with the last subject visit anticipated in April. CB4211, the first mitochondria-based therapeutic, aims to tackle the unmet medical need in NASH affecting millions. The study focuses on safety, tolerability, and potential improvements in liver fat and weight, marking a significant milestone in CohBar's therapeutic development.
CohBar (NASDAQ: CWBR) plans to release its Q4 2020 financial results on March 30, 2021, after market close. Management will host a conference call with a live slide presentation at 5:00 p.m. ET to discuss business updates. Participants can join by dialing (877) 451-6152 for U.S. and Canadian listeners or (201) 389-0879 internationally. The presentation can also be accessed via CohBar's website. An audio replay will be available until April 20, 2021.
CohBar (NASDAQ: CWBR) has selected CB5138-3 as its lead candidate for further development targeting Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. This follows positive preclinical results demonstrating its effectiveness in reducing fibrosis and inflammation in mouse models. Currently, IPF affects around 100,000 individuals in the U.S. and has limited treatment options. The company plans to initiate IND-enabling activities for CB5138-3, with hopes to begin clinical studies in 2022, while also evaluating its effects on other fibrotic diseases.
CohBar, a clinical stage biotechnology company, announced that CEO Steven Engle will participate in a fireside chat with analyst Jason McCarthy at the Emerging Growth Conference from March 17-19, 2021. Engle will present a company overview, available on demand. The conference will showcase CohBar’s focus on mitochondria-based therapeutics aimed at treating chronic diseases. Their lead compound, CB4211, is currently in Phase 1b clinical trials for NASH and obesity, while four other preclinical programs target various diseases.
CohBar, Inc. (NASDAQ: CWBR) announced that CEO Steven Engle will participate in a fireside chat with ROTH Senior Analyst Elemer Piros, Ph.D. during the 33rd Annual ROTH Conference from March 15-17, 2021. The event will include a presentation on March 16 at 2:00 PM ET, available via webcast. CohBar focuses on developing mitochondria-based therapeutics to treat chronic diseases, with its lead compound, CB4211, currently in Phase 1b trials for NASH and obesity. The company has also established several preclinical programs targeting various health conditions.
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company, announced that its CEO, Steven Engle, will present a company overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The conference will be held virtually, with a presentation accessible via a webcast link. CohBar focuses on mitochondria-based therapeutics for chronic diseases, with its lead compound, CB4211, currently in Phase 1b trials for NASH and obesity. The company has also developed several peptide analogs targeting various diseases including COVID-19.
CohBar, Inc. (NASDAQ: CWBR) announced that CEO Steven Engle will present a company overview at the BIO CEO & Investor Digital Conference from February 16-18, 2021. This presentation will be on demand for registered attendees. CohBar focuses on developing mitochondria-based therapeutics for chronic diseases and has discovered over 100 mitochondrial-derived peptides. Currently, its lead compound, CB4211, is in Phase 1b clinical trials for NASH and obesity, with additional preclinical programs targeting various diseases including cancers and COVID-19 related complications.
FAQ
What is the current stock price of COHBAR (CWBR)?
What is the market cap of COHBAR (CWBR)?
What does CohBar Inc. specialize in?
What are Mitochondria-Based Therapeutics (MBTs)?
Who founded CohBar Inc.?
What recent achievements has CohBar made?
What diseases are targeted by CohBar’s therapies?
Is CohBar financially stable?
How does CohBar collaborate with other entities?
What is the significance of the proposed merger with Morphogenesis?
How can investors get in touch with CohBar?
Where can I find more information about CohBar?
